Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.60    -0.10 (-3.70%)
Bid:
2.60
Ask:
2.66
Spread: 0.06 (2.308%)
Market Cap: £2.68m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Market Update

8 Jul 2022 07:00

RNS Number : 7671R
Litigation Capital Management Ltd
08 July 2022
 

8 July 2022

 

Litigation Capital Management Limited

(LCM or the Company)

 

Market Update

 

 

Litigation Capital Management Limited (AIM:LIT), a leading alternate asset manager of disputes financing solutions, provides a market update for the twelve month period to 30 June 2022 ("FY 2022").

 

Based on unaudited management accounts the Group expects to report positive growth in its financial performance compared to the comparative period covering the twelve months to 30 June 2021 ("FY 2021"), this is despite previously reported disruption and delay in justice systems. FY 2022 gross revenue is expected to be approximately 25% higher than FY 2021, with adjusted operating profit approximately 15% higher. Cash held at period end is A$29m and total assets under management increased to A$414m. A decrease in overall applications during the period reflected disrupted trading conditions, however commitments were broadly in line with the prior year, indicating progress on improving the quality of applications.

 

The Company had two material investments move into future financial periods. Whilst such delays are diminishing, they are still present in our portfolio. The financial performance of those investments will not be adversely impacted by the delay indeed it may be enhanced. As previously disclosed, this is purely a timing issue and is not an indication of LCM's current or future financial performance, nor should it be taken as a direct move of such cases into the following period forecasts as the collective portfolio and timing of resolutions is continually assessed based on how investments are progressing through either the court or arbitral cycle.

 

The degree of complexity in investments made by the Company means that whilst LCM has extensive experience in the provision of disputes funding and finance products to the market, that accurate forward forecasting is exceptionally difficult to achieve. It requires the financier to predict accurately when a particular investment, or portfolio of investments, will come to a conclusion either through a negotiated settlement of the dispute or an adjudication by a court or tribunal. Secondly, it requires the financier to predict the quantum of such a resolution, either as a negotiated settlement or as an award by the court or tribunal. Given the myriad of possible outcomes in respect of an investment in a dispute, it is not reasonable or responsible to provide market guidance.

 

Patrick Moloney, Chief Executive Officer, commented: "I'm pleased with our resilient performance for the second half of the financial year, despite continued challenging external conditions, in which we have maintained our level of commitments alongside growing our assets under management.

 

"Noting that the average life of these investments is historically 27 months, as our investments become larger and more complex, we expect the investment period to increase to between 36 and 42 months.

 

"With the current market instability and uncertainty, we remain very confident in LCM's growth prospects."

 

Enquiries

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

Alma PR

Tel: 020 3405 0205

Justine James

Kieran Breheny

LCM@almapr.co.uk

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) is a global provider of disputes finance. LCM provides capital and risk management services into the disputes market including insolvency, commercial disputes, arbitral disputes, class actions and corporate portfolios.

LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management.

 

Current headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSAESWEESESW
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.